The Association between Lifestyle Choices and Schizophrenia Symptoms
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Participants
2.2. Psychometric Evaluation, Lifestyle Assessment, Anthropometric Measurements, Blood Pressure, and Biochemical Parameters
- -
- weight of consumed sweets (in g/day),
- -
- volume of sweetened carbonated drinks (in mL/day),
- -
- amount of sugar used (in teaspoons/day),
- -
- volume of coffee and strong tea drunk per day (1 tea or coffee = 250 mL),
- -
- number of cigarettes smoked (no/day).
- -
- 1 was low physical activity (sedentary lifestyle),
- -
- 2 was moderate physical activity (physical activity performed to attend to routine daily duties)
- -
- 3 was intense physical activity (physical activity undertaken at least 3× per week for ≥30 min).
2.3. Statistical Analysis
3. Results
3.1. General Observations
3.2. Correlations between Smoking, Eating Habits, Physical Activity and Biochemical Parameters
3.3. Correlations between Smoking, Eating Habits, Physical Activity and PANSS Scores
3.4. Gender Differences
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Ratliff, J.C.; Palmese, L.B.; Reutenauer, E.L.; Liskov, E.; Grilo, C.M.; Tek, C. The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: A cross-sectional study. Compr. Psychiatry 2012, 53, 1028–1033. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vancampfort, D.; Knapen, J.; Probst, M.; van Winkel, R.; Deckx, S.; Maurissen, K.; Peuskens, J.; De Hert, M. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia. Psychiatry Res. 2010, 177, 271–279. [Google Scholar] [CrossRef]
- Heald, A.; Pendlebury, J.; Anderson, S.; Narayan, V.; Guy, M.; Gibson, M.; Haddad, P.; Livingston, M. Lifestyle factors and the metabolic syndrome in Schizophrenia: A cross-sectional study. Ann. Gen. Psychiatry 2017, 16, 12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Allison, D.B.; Newcomer, J.W.; Dunn, A.L.; Blumenthal, J.A.; Fabricatore, A.N.; Daumit, G.L.; Cope, M.B.; Riley, W.T.; Vreeland, B.; Hibbeln, J.R.; et al. Obesity among those with mental disorders: A national institute of mental health meeting report. Am. J. Prev. Med. 2009, 36, 341–350. [Google Scholar] [CrossRef] [PubMed]
- De Hert, M.; Detraux, J.; van Winkel, R.; Yu, W.; Correll, C.U. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2011, 8, 114–126. [Google Scholar] [CrossRef] [PubMed]
- Capasso, R.M.; Lineberry, T.W.; Bostwick, J.M.; Decker, P.A.; St Sauver, J. Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950-2005. Schizophr. Res. 2008, 98, 287–294. [Google Scholar] [CrossRef]
- Teasdale, S.B.; Ward, P.B.; Samaras, K.; Firth, J.; Stubbs, B.; Tripodi, E.; Burrows, T.L. Dietary intake of people with severe mental illness: Systematic review and meta-analysis. Br. J. Psychiatry 2019, 214, 251–259. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Strassing, M.; Brar, J.S.; Ganguli, R. Body mass index and quality of life in community-dwelling patients with schizophrenia. Schizophr Res. 2003, 62, 73–76. [Google Scholar] [CrossRef]
- Strassing, M.; Brar, J.S.; Ganguli, R. Nutritional assessment of patients with schizophrenia: A preliminary study. Schizophr. Bull. 2003, 29, 393–397. [Google Scholar] [CrossRef] [Green Version]
- Henderson, D.C.; Borba, C.P.; Daley, T.B.; Boxill, R.; Nguyen, D.D.; Culhane, M.A.; Louie, P.; Cather, C.; Evins, A.E.; Freudenreich, O.; et al. Dietary intake profile of patients with schizophrenia. Ann. Clin. Psychiatry 2006, 18, 99–105. [Google Scholar] [CrossRef]
- Wendołowicz, A.; Stefańska, E.; Jankowska, D.; Waszkiewicz, N.; Ostrowska, L. Intake of selected nutraceuticals and the clinical condition of patients with mental disorders. Arch. Psychiatry Psychother. 2020, 3, 17–29. [Google Scholar] [CrossRef]
- de Leon, J.; Diaz, F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76, 135–157. [Google Scholar] [CrossRef] [PubMed]
- Rüther, T.; Bobes, J.; De Hert, M.; Svensson, T.H.; Mann, K.; Batra, A.; Gorwood, P.; Möller, H.J. European Psychiatric Association. EPA guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur. Psychiatry 2014, 29, 65–82. [Google Scholar] [CrossRef] [Green Version]
- Dzien, A.; Dzien-Bischinger, C.; Hoppichler, F.; Lechleitner, M. The metabolic syndrome as a link between smoking and cardiovascular disease. Diabetes Obes. Metab. 2004, 6, 127–132. [Google Scholar] [CrossRef]
- Kumari, V.; Postma, P. Nicotine use in schizophrenia: The self medication hypotheses. Neurosci. Biobehav. Rev. 2005, 29, 1021–1034. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.F.; Hu, T.M.; Lan, T.H.; Chiu, H.J.; Sheen, L.Y.; Loh, E.W. Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: Severe negative syndrome may be related to a distinct lipid pathophysiology. Eur. Psychiatry 2014, 29, 167–171. [Google Scholar] [CrossRef]
- Jakobsen, A.S.; Speyer, H.; Nørgaard, H.C.B.; Karlsen, M.; Hjorthøj, C.; Krogh, J.; Mors, O.; Nordentoft, M.; Toft, U. Dietary patterns and physical activity in people with schizophrenia and increased waist circumference. Schizophr. Res. 2018, 199, 109–115. [Google Scholar] [CrossRef]
- Wichniak, A.; Skowerska, A.; Chojnacka-Wójtowicz, J.; Tafliński, T.; Wierzbicka, A.; Jernajczyk, W.; Jarema, M. Actigraphic monitoring of activity and rest in schizophrenic patients treated with olanzapine or risperidone. J. Psychiatr. Res. 2011, 45, 1381–1386. [Google Scholar] [CrossRef]
- Nyboe, L.; Moeller, M.K.; Vestergaard, C.H.; Lund, H.; Videbech, P. Physical activity and anomalous bodily experiences in patients with first-episode schizophrenia. Nord. J. Psychiatry 2016, 70, 1–7. [Google Scholar] [CrossRef]
- Kalinowska, S.; Trześniowska-Drukała, B.; Safranow, K.; Pełka-Wysiecka, J.; Kłoda, K.; Misiak, B.; Samochowiec, J. Association between thyroid function and metabolic syndrome in male and female schizophrenia patients. Psychiatry Res. 2019, 274, 167–175. [Google Scholar] [CrossRef]
- Hasnain, M.; Vieweg, R.V.W. Do we truly appreciate how difficult it is for patients with schizophrenia to adapt a healthy lifestyle? Acta Psychiatr. Scand. 2011, 123, 409–410. [Google Scholar] [CrossRef] [PubMed]
- Chen, S.; Broqueres-You, D.; Yang, G.; Wang, Z.; Li, Y.; Yang, F.; Tan, Y. Male sex may be associated with higher metabolic risk in first-episode schizophrenia patients: A preliminary study. Asian J. Psychiatry 2016, 21, 25–30. [Google Scholar] [CrossRef] [PubMed]
- Evan, S.; Newton, R.; Higgins, S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: A randomized controlled trial. Aust. N. Z. J. Psychiatry 2005, 39, 479–486. [Google Scholar] [CrossRef]
- Andreasen, N.C.; Pressler, M.; Nopoulos, P.; Miller, D.; Ho, B.C. Antipsychotic dose equivalents and dose-years: A standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67, 255–262. [Google Scholar] [CrossRef] [Green Version]
- Danivas, V.; Venkatasubramanian, G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J. Psychiatry 2013, 55, 207–208. [Google Scholar]
- Kay, S.R.; Fiszbein, A.; Opler, L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13, 261–276. [Google Scholar] [CrossRef]
- Bly, M.J.; Taylor, S.F.; Dalack, G.; Pop-Busui, R.; Burghardt, K.J.; Evans, S.J.; McInnis, M.I.; Grove, T.B.; Brook, R.D.; Zöllner, S.K.; et al. Metabolic syndrome in bipolar disorder and schizophrenia: Dietary and lifestyle factors compared to the general population. Bipolar Disord. 2014, 16, 277–288. [Google Scholar] [CrossRef] [Green Version]
- McCreadie, R.G.; Kelly, C.; Connolly, M.; Williams, S.; Baxter, G.; Lean, M.; Paterson, J.R. Dietary improvement in people with schizophrenia: Randomised controlled trial. Br. J. Psychiatry 2005, 187, 346–351. [Google Scholar] [CrossRef] [Green Version]
- Aquila, R.; Emanuel, M. Interventions for weight gain in adults treated with novel Antipsychotics. Prim. Care Companion J. Clin. Psychiatry 2000, 2, 20–23. [Google Scholar] [CrossRef] [Green Version]
- Menza, M.; Vreeland, B.; Minsky, S.; Gara, M.; Radler, D.R.; Sakowitz, M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J. Clin. Psychiatry 2004, 65, 471–477. [Google Scholar] [CrossRef]
- Wu, M.K.; Wang, C.K.; Bai, Y.M.; Huang, C.Y.; Lee, S.D. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr. Serv. 2007, 58, 544–550. [Google Scholar] [CrossRef] [PubMed]
- Kimhy, D.; Vakhrusheva, J.; Bartels, M.N.; Armstrong, H.F.; Ballon, J.S.; Khan, S.; Chang, R.W.; Hansen, M.C.; Ayanruoh, L.; Smith, E.E.; et al. Aerobic fitness and body mass index in individuals with schizophrenia: Implications for neurocognition and daily functioning. Psychiatry Res. 2014, 220, 784–791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malchow, B.; Keller, K.; Hasan, A.; Dörfler, S.; Schneider-Axmann, T.; Hillmer-Vogel, U.; Honer, W.G.; Schulze, T.G.; Niklas, A.; Wobrock, T.; et al. Effects of endurance training combined with cognitive remediation on everyday functioning, symptoms, and cognition in multiepisode Schizophrenia patients. Schizophr. Bull. 2015, 41, 847–858. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chen, J.; Bacanu, S.A.; Yu, H.; Zhao, Z.; Jia, P.; Kendler, K.S.; Kranzler, H.R.; Gelernter, J.; Farrer, L.; Minica, C.; et al. Cotinine meta-analysis group, and FTND meta-analysis group (2016) genetic relationship between Schizophrenia and Nicotine dependence. Sci. Rep. 2016, 6, 256–271. [Google Scholar]
- Hu, Y.; Fang, Z.; Yang, Y.; Rohlsen-Neal, D.; Cheng, F.; Wang, J. Analyzing the genes related to nicotine addiction or schizophrenia via a pathway and network based approach. Sci. Rep. 2018, 8, 2894. [Google Scholar] [CrossRef] [Green Version]
- Gage, S.H.; Jones, H.J.; Taylor, A.E.; Burgess, S.; Zammit, S.; Munafò, M.R. Investigating causality in associations between smoking initiation and schizophrenia using mendelian randomization. Sci. Rep. 2017, 19, 406–453. [Google Scholar] [CrossRef] [Green Version]
- Bobes, J.; Arango, C.; Garcia-Garcia, M.; Rejas, J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophr. Res. 2010, 119, 101–109. [Google Scholar] [CrossRef]
- An, H.-M.; Tan, Y.-L.; Tan, S.-P.; Shi, J.; Wang, Z.-R.; Yang, F.-D.; Huang, X.-F.; Soars, J.C.; Kosten, T.R.; Zhang, X.-Y. Smoking and serum lipid profiles in Schizophrenia. Neurosci. Bull. 2016, 32, 383–388. [Google Scholar] [CrossRef] [Green Version]
- Osuji, P.; Onu, J. Feeding behaviors among incident cases of schizophrenia in a psychiatric hospital: Association with dimensions of psychopathology and social suport. Clin. Nutr. ESPEN 2019, 34, 125–129. [Google Scholar] [CrossRef]
- Adamowicz, K.; Kucharska-Mazur, J. Dietary behaviors and metabolic syndrome in schizophrenia patients. J. Clin. Med. 2020, 9, 537. [Google Scholar] [CrossRef] [Green Version]
Measured Parameters | T1 (n = 106) Mean ± SD or % | T2 (n = 102) Mean ± SD or % |
---|---|---|
Height (cm) | 169.9 ± 9.78 | - |
Body weight (kg) | 84.3 ± 20.9 | 83.22 ± 19.78 |
BMI (kg/m2) | 29.16 ± 8.86 | 29.16 ± 8.86 |
CIGARETTES (no/d) | 8.01 ± 10.01 | 7.14 ± 9.20 |
COFFEE (mL/d) | 1.11 ± 1.22 | 0.95 ± 1.00 |
TEA (mL/d) | 1.04 ± 1.28 | 0.96 ± 1.23 |
SWEETS (g/d) | 31.88 ± 56.20 | 15.2 ± 35.67 |
SODAS (mL/d) | 69.33 ± 319.86 | 63.72 ± 324.20 |
SUGAR (tblsp/d) | 1.57 ± 2.55 | 0.93 ± 1.49 |
Low physical activity (N of participants) | 15/14.15 | 16/15.68 |
Moderate physical activity (N of participants) | 71/66.98 | 64/62.74 |
Intense physical activity (N of participants) | 20/18.86 | 22/21.56 |
CHOL-T (mg/dL) | 193.54 ± 44.43 | 190.7± 40.35 |
TG (mg/dL) | 159.27 ± 89 | 158.95 ± 90.39 |
LDL (mg/dL) | 121.9 ± 37.18 | 120.17 ± 34.90 |
HDL (mg/dL) | 48.15 ± 13.58 | 48.63 ± 13.34 |
Blood glucose (mg/dL) | 99.16 ± 35.55 | 94.23 ± 20.85 |
SBP (mmHg) | 121.46 ± 10.55 | 119.06 ± 9.27 |
DBP (mmHg) | 74.67 ± 8.87 | 74.8 ± 7.92 |
PANSS (pt) | 55.75 ± 21.19 | 44.45 ± 11.21 |
P (pt) | 12.57 ± 6.78 | 9.23 ± 3.00 |
N (pt) | 15.58 ± 6.36 | 12.71 ± 4.08 |
G (pt) | 27.68 ± 10.64 | 22.60 ± 6.39 |
Correlation | T1 (n = 106) | T2 (n = 102) | ||
---|---|---|---|---|
r | p * | r | p * | |
CIGARETTES and CHOL-T | 0.19 | 0.04 | 0.23 | 0.02 |
CIGARETTES and TG | 0.12 | 0.19 | 0.17 | 0.09 |
CIGARETTES and HDL | −0.21 | 0.02 | −0.18 | 0.064 |
CIGARETTES and LDL | 0.2 | 0.03 | 0.22 | 0.03 |
CIGARETTES and BLOOD GLUCOSE | −0.05 | 0.55 | −0.16 | 0.11 |
SWEETS and CHOL-T | 0.12 | 0.20 | 0.039 | 0.69 |
SWEETS and TG | 0.27 | 0.004 | 0.076 | 0.44 |
SWEETS and HDL | −0.31 | 0.0008 | −0.17 | 0.09 |
SWEETS and LDL | 0.13 | 0.15 | 0.15 | 0.13 |
SUGAR and CHOL-T | 0.23 | 0.014 | 0.17 | 0.088 |
SUGAR and TG | 0.17 | 0.06 | 0.014 | 0.89 |
SUGAR and HDL | −0.09 | 0.35 | 0.099 | 0.32 |
SUGAR and LDL | 0.20 | 0.03 | 0.085 | 0.40 |
SODAS and CHOL-T | −0.02 | 0.81 | 0.11 | 0.25 |
SODAS and TG | 0.22 | 0.01 | 0.17 | 0.08 |
SODAS and HDL | −0.24 | 0.01 | −0.19 | 0.05 |
SODAS and LDL | 0.01 | 0.87 | 0.15 | 0.13 |
COFFEE and CHOL-T | 0.21 | 0.02 | 0.19 | 0.055 |
COFFEE and TG | 0.22 | 0.02 | 0.12 | 0.22 |
COFFEE and HDL | −0.15 | 0.11 | −0.13 | 0.19 |
COFFEE and LDL | 0.21 | 0.02 | 0.22 | 0.028 |
COFFEE and BLOOD GLUCOSE | 0.09 | 0.34 | −0.12 | 0.24 |
PHYSICAL ACTIVITY and CHOL-T | −0.16 | 0.09 | −0.089 | 0.37 |
PHYSICAL ACTIVITY and TG | −0.25 | 0.009 | −0.305 | 0.002 |
PHYSICAL ACTIVITY and HDL | 0.21 | 0.03 | 0.17 | 0.09 |
PHYSICAL ACTIVITY and LDL | −0.18 | 0.05 | −0.051 | 0.608 |
PHYSICAL ACTIVITY and BLOOD GLUCOSE | −0.14 | 0.14 | −0.14 | 0.17 |
Correlation | T1 (n = 106) | T2 (n = 102) | ||
---|---|---|---|---|
r | p * | r | p * | |
CIGARETTES and PANSS | −0.114 | 0.24 | −0.11 | 0.25 |
CIGARETTES and P | 0.010 | 0.91 | 0.018 | 0.86 |
CIGARETTES and N | −0.23 | 0.018 | −0.20 | 0.046 |
CIGARETTES and G | −0.047 | 0.63 | −0.11 | 0.26 |
SWEETS and PANSS | −0.28 | 0.003 | −0.16 | 0.1 |
SWEETS and P | −0.24 | 0.012 | −0.085 | 0.39 |
SWEETS and N | −0.15 | 0.12 | −0.0501 | 0.62 |
SWEETS and G | −0.33 | 0.0005 | −0.21 | 0.03 |
SODAS and PANSS | 0.033 | 0.73 | −0.12 | 0.24 |
SODAS and P | 0.016 | 0.87 | −0.12 | 0.24 |
SODAS and N | 0.069 | 0.48 | −0.0059 | 0.95 |
SODAS and G | 0.046 | 0.64 | −0.20 | 0.045 |
SUGAR and PANSS | −0.090 | 0.35 | 0.027 | 0.78 |
SUGAR and P | −0.031 | 0.75 | 0.12 | 0.21 |
SUGAR and N | −0.035 | 0.71 | −0.043 | 0.66 |
SUGAR and G | −0.142 | 0.14 | −0.0039 | 0.97 |
COFFEE and PANSS | −0.20 | 0.034 | −0.08 | 0.38 |
COFFEE and P | −0.05 | 0.59 | 0.07 | 0.46 |
COFFEE and N | −0.22 | 0.02 | −0.1 | 0.3 |
COFFEE and G | −0.21 | 0.02 | −0.13 | 0.16 |
PHYSICAL ACTIVITY and PANSS | −0.24 | 0.014 | −0.408 | 0.00002 |
PHYSICAL ACTIVITY and P | −0.052 | 0.59 | −0.23 | 0.018 |
PHYSICAL ACTIVITY and N | −0.33 | 0.0006 | −0.43 | 0.000005 |
PHYSICAL ACTIVITY and G | −0.22 | 0.019 | −0.33 | 0.00069 |
T1 (n = 106) | T2 (n = 102) | |||||||
---|---|---|---|---|---|---|---|---|
Parameter | F (n = 64) | M (n = 42) | p-Value | F (n = 63) | M (n = 39) | p-Value | ||
Mean ± SD or N (%) | Mean ± SD or N (%) | Mean ± SD or N (%) | Mean ± SD or N (%) | |||||
HABITS | CIGARETTES (no/d) | 8.01 ± 10.03 | 8.02 ± 10.11 | 0.94 | 6.90 ± 8.76 | 7.53 ± 9.98 | 0.89 | |
SWEETS (g/d) | 23.25 ± 46.26 | 44.88 ± 67.18 | 0.03 | 10.87 ± 28.23 | 22.30 ± 44.70 | 0.1 | ||
SODAS (mL/d) | 6.25 ± 24.39 | 165.47 ± 494.40 | 0.0009 | 6.98 ± 27.39 | 155.38 ± 513.98 | 0.01 | ||
SUGAR (tblsp/d) | 1.48 ± 2.82 | 1.71 ± 2.08 | 0.25 | 0.76 ± 1.02 | 1.21 ± 2.01 | 0.59 | ||
COFFEE (mL/d) | 1.01 ± 1.17 | 1.26 ± 9.98 | 0.35 | 0.84 ± 0.93 | 1.12 ± 1.10 | 0.20 | ||
* PHYSICAL ACTIVITY | LOW | 6 (9.4) | 9 (21.4) | 0.086 * | 6 (9.5) | 10 (25.6) | 0.09 * | |
MODERATE | 44 (68.8) | 27 (64.3) | 43 (68.3) | 21 (53.8) | ||||
INTENSE | 14 (21.9) | 6 (14.3) | 14 (22.2) | 8 (20.5) | ||||
PANSS | TOTAL SCORE (pt) | 54.42 ± 20.05 | 57.73 ± 22.92 | 0.52 | 42.44 ± 8.70 | 47.69 ± 13.89 | 0.06 | |
P (pt) | 12.31 ± 6.34 | 12.97 ± 7.46 | 0.88 | 8.93 ± 2.85 | 9.71 ± 3.21 | 0.24 | ||
N (pt) | 14.68 ± 5.75 | 16.95 ± 7.06 | 0.06 | 11.71 ± 2.73 | 14.33 ± 5.26 | 0.01 | ||
G (pt) | 27.45 ± 10.30 | 28.04 ± 1.24 | 0.94 | 21.67 ± 4.58 | 24.12 ± 8.39 | 0.32 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kalinowska, S.; Trześniowska-Drukała, B.; Kłoda, K.; Safranow, K.; Misiak, B.; Cyran, A.; Samochowiec, J. The Association between Lifestyle Choices and Schizophrenia Symptoms. J. Clin. Med. 2021, 10, 165. https://doi.org/10.3390/jcm10010165
Kalinowska S, Trześniowska-Drukała B, Kłoda K, Safranow K, Misiak B, Cyran A, Samochowiec J. The Association between Lifestyle Choices and Schizophrenia Symptoms. Journal of Clinical Medicine. 2021; 10(1):165. https://doi.org/10.3390/jcm10010165
Chicago/Turabian StyleKalinowska, Sylwia, Beata Trześniowska-Drukała, Karolina Kłoda, Krzysztof Safranow, Błażej Misiak, Agnieszka Cyran, and Jerzy Samochowiec. 2021. "The Association between Lifestyle Choices and Schizophrenia Symptoms" Journal of Clinical Medicine 10, no. 1: 165. https://doi.org/10.3390/jcm10010165
APA StyleKalinowska, S., Trześniowska-Drukała, B., Kłoda, K., Safranow, K., Misiak, B., Cyran, A., & Samochowiec, J. (2021). The Association between Lifestyle Choices and Schizophrenia Symptoms. Journal of Clinical Medicine, 10(1), 165. https://doi.org/10.3390/jcm10010165